Company research
Amneal Pharmaceuticals, Inc.
CIK 1723128Updated Sep 24, 2026
SecurityAMRX · NASDAQ · equity
Name history
Atlas Holdings, Inc. · through Apr 13, 2018
AMRX price & chart
Loading TradingView…
NASDAQ:AMRX on TradingView ↗About the company
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.
In the news
Amneal to Report Second Quarter 2026 Results on July 30, 2026 ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,678,280,000Source | 3,501,445,000Source | 3,472,569,000Source | 3,799,341,000Source |
| Property, Plant and Equipment, NetUSD | 442,950,000Source | 424,908,000Source | 447,574,000Source | 469,815,000Source |
| GoodwillUSD | 595,470,000Source | 597,436,000Source | 598,629,000Source | 598,853,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 563,498,000Source | 732,377,000Source | 890,423,000Source | 1,096,093,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 282,029,000Source | 110,552,000Source | 91,542,000Source | 25,976,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 741,791,000Source |
| Inventory, NetUSD | 606,302,000Source | 612,454,000Source | 581,384,000Source | 530,735,000Source |
| Assets, CurrentUSD | 1,911,181,000Source | 1,587,806,000Source | 1,377,863,000Source | 1,411,818,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 98,395,000Source | 80,717,000Source | 82,685,000Source | 103,565,000Source |
| Operating Lease, Right-of-Use AssetUSD | 54,048,000Source | 42,352,000Source | 43,283,000Source | 56,121,000Source |
| Other Assets, NoncurrentUSD | 57,805,000Source | 60,133,000Source | 55,517,000Source | 103,217,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 571,794,000Source | 560,206,000Source | 539,240,000Source | 691,629,000Source |
| Retained Earnings (Accumulated Deficit)USD | -535,005,000Source | -607,062,000Source | -490,176,000Source | -406,183,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -110,729,000Source | -65,510,000Source | -32,349,000Source | 9,939,000Source |
| Stockholders' Equity Attributable to ParentUSD | -70,794,000Source | -109,267,000Source | 19,781,000Source | 298,421,000Source |
| Liabilities and EquityUSD | 3,678,280,000Source | 3,501,445,000Source | 3,472,569,000Source | 3,799,341,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 881,633,000Source | 1,129,771,000Source | 846,595,000Source | 752,800,000Source |
| Accounts Payable, CurrentUSD | — | — | — | 165,980,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | 87,468,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -535,000Source | -245,000Source | 230,000Source | -114,442,000Source |
| Additional Financial Items | ||||
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 6,761,000Source | 224,213,000Source | 34,125,000Source | 29,961,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 2,565,115,000Source | 2,161,790,000Source | 2,386,004,000Source | 2,591,981,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 127,933,000Source | -73,876,000Source | -48,722,000Source | -254,789,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 31,953,000Source | 27,768,000Source | 26,822,000Source | 31,847,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 120,566,000Source | 162,637,000Source | -126,289,000Source | 79,717,000Source |
| Increase (Decrease) in InventoriesUSD | 87,026,000Source | 130,530,000Source | 126,182,000Source | 102,396,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 339,992,000Source | 295,099,000Source | 345,577,000Source | 65,100,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 0Source | 0Source | 84,714,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -112,263,000Source | -62,996,000Source | -69,189,000Source | -174,309,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 70,063,000Source | 51,924,000Source | 43,216,000Source | 46,407,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 22,278,000Source | 7,952,000Source | 2,378,000Source | 3,571,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -31,530,000Source | -211,791,000Source | -212,573,000Source | -106,620,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 194,519,000Source | 19,313,000Source | 63,880,000Source | -221,512,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 312,939,000Source | 118,420,000Source | 99,107,000Source | 35,227,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 197,848,000Source | 263,518,000Source | 192,806,000Source | 142,722,000Source |
| Income Taxes Paid, NetUSD | 21,327,000Source | 15,220,000Source | -2,496,000Source | -12,649,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -1,680,000Source | -999,000Source | 65,000Source | -5,683,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 31,953,000Source | 27,768,000Source | 26,822,000Source | 31,847,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 22,431,000Source | 29,097,000Source | 8,182,000Source | 8,595,000Source |
| Amortization of Intangible AssetsUSD | 166,300,000Source | 173,600,000Source | 163,200,000Source | 172,063,000Source |
| DepreciationUSD | 57,300,000Source | 62,600,000Source | 66,200,000Source | 68,112,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 7,635,000Source | -6,846,000Source | 1,671,000Source | -12,364,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 7,453,000Source | -7,191,000Source | 768,000Source | -15,190,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | 390,000Source | -96,692,000Source | -1,824,000Source | -269,930,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -31,365,000Source | 0Source | -40,805,000Source | -291,000Source |
| GoodwillUSD | 595,470,000Source | 597,436,000Source | 598,629,000Source | 598,853,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | — | 0Source | 0Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 22,784,000Source | 920,000Source | 66,932,000Source | 24,081,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | 24,100,000Source |
| Income Tax Expense (Benefit)USD | 11,276,000Source | 18,863,000Source | 8,452,000Source | 6,662,000Source |
| Inventory Write-downUSD | 85,962,000Source | 96,558,000Source | 74,686,000Source | 51,096,000Source |
| Net Income (Loss) Attributable to ParentUSD | 72,057,000Source | — | -79,265,000Source | -270,584,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 55,876,000Source | 43,010,000Source | 35,271,000Source | -125,241,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 72,057,000Source | -116,886,000Source | -83,993,000Source | -129,986,000Source |
| Nonoperating Income (Expense)USD | -254,887,000Source | -304,339,000Source | -244,644,000Source | -153,199,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | 0Source |
| Other Nonoperating Income (Expense)USD | 16,522,000Source | 11,782,000Source | 5,119,000Source | 17,833,000Source |
| Other Operating Income (Expense), NetUSD | 5,240,000Source | 0Source | 1,138,000Source | 3,960,000Source |
| Payments of Financing CostsUSD | — | — | 162,415,000Source | 1,663,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,960,000Source | 1,154,000Source | 451,000Source | 662,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,018,760,000Source | 2,793,957,000Source | 2,393,607,000Source | 2,212,304,000Source |
| Cost of RevenueUSD | 1,905,452,000Source | 1,773,519,000Source | 1,573,042,000Source | 1,416,485,000Source |
| Selling, General and Administrative ExpenseUSD | 526,827,000Source | 476,436,000Source | 429,675,000Source | 399,700,000Source |
| Operating Income (Loss)USD | 394,096,000Source | 249,326,000Source | 204,374,000Source | -94,928,000Source |
| Other Nonoperating Income (Expense)USD | 16,522,000Source | 11,782,000Source | 5,119,000Source | 17,833,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 139,209,000Source | -55,013,000Source | -40,270,000Source | -248,127,000Source |
| Income Tax Expense (Benefit)USD | 11,276,000Source | 18,863,000Source | 8,452,000Source | 6,662,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 55,876,000Source | 43,010,000Source | 35,271,000Source | -125,241,000Source |
| Net Income (Loss) Attributable to ParentUSD | 72,057,000Source | — | -79,265,000Source | -270,584,000Source |
| Earnings Per Share, BasicUSD per share | 0.23Source | -0.38Source | -0.48Source | -0.86Source |
| Earnings Per Share, DilutedUSD per share | 0.22Source | -0.38Source | -0.48Source | -0.86Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 313,367,000Source | 308,978,000Source | 176,136,000Source | 150,944,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 324,805,000Source | 308,978,000Source | 176,136,000Source | 150,944,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 166,300,000Source | 173,600,000Source | 163,200,000Source | 172,063,000Source |
| Business Combination, Acquisition Related CostsUSD | — | — | — | 700,000Source |
| Current Income Tax Expense (Benefit)USD | 11,276,000Source | 18,863,000Source | 8,452,000Source | 6,662,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 7,635,000Source | -6,846,000Source | 1,671,000Source | -12,364,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | 390,000Source | -96,692,000Source | -1,824,000Source | -269,930,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 0Source | — |
| Gross ProfitUSD | 1,113,308,000Source | 1,020,438,000Source | 820,565,000Source | 784,708,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -241,091,000Source | -258,595,000Source | -210,629,000Source | -158,377,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 72,057,000Source | -116,886,000Source | -83,993,000Source | -129,986,000Source |
| Nonoperating Income (Expense)USD | -254,887,000Source | -304,339,000Source | -244,644,000Source | -153,199,000Source |
| Other Operating IncomeUSD | — | — | 1,200,000Source | 4,000,000Source |
| Other Operating Income (Expense), NetUSD | 5,240,000Source | 0Source | 1,138,000Source | 3,960,000Source |
| Research and Development ExpenseUSD | 186,175,000Source | 190,714,000Source | 163,950,000Source | 195,688,000Source |
Filing attachments
ef20079825_ex99-1.htm · 8-K · 2026-08-10
EX-99.1 4 ef20079825_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal’s growth profile into the 2030s BRIDGEWATER, N.J., August 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completi…
Read attachment ↗amrx-q22026ex991.htm · 8-K · 2026-07-30
EX-99.1 2 amrx-q22026ex991.htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS - Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 - - Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 - - Raising 2026 Full Year Guidance - - Successful Debt Repricing in July Reduces Interest Cost - BRIDGEWATER, NJ, July 30, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) …
Read attachment ↗amrx-q12026ex991.htm · 8-K · 2026-05-07
EX-99.1 2 amrx-q12026ex991.htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒ BRIDGEWATER, NJ, May 7, 2026 - Amneal Pharmaceuticals, …
Read attachment ↗d126526dex991.htm · 8-K · 2026-04-22
EX-99.1 5 d126526dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance - Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity - - Transaction Accelerates Growth Profile and Diversification - - Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance - - Company…
Read attachment ↗amrx-q42025ex991.htm · 8-K · 2026-02-27
EX-99.1 2 amrx-q42025ex991.htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth - ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.…
Read attachment ↗amrx-q32025ex991.htm · 8-K · 2025-10-30
EX-99.1 2 amrx-q32025ex991.htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS ‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, NJ, October 30, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended Sept…
Read attachment ↗